[HTML][HTML] Dual bronchodilators in chronic obstructive pulmonary disease: Evidence from randomized controlled trials and real-world studies
A Anzueto, A Kaplan - Respiratory Medicine: X, 2020 - Elsevier
Purpose Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a
long-acting β 2-agonist (LABA) is recommended in the pharmacological management of …
long-acting β 2-agonist (LABA) is recommended in the pharmacological management of …
Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review
JL Lopez-Campos, C Calero-Acuña… - … Journal of Chronic …, 2017 - Taylor & Francis
Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
[HTML][HTML] Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
DP Tashkin, GT Ferguson - Respiratory research, 2013 - Springer
Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …
Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized …
H Chen, K Wang, T Yuan, X Wang, L Huanng… - International …, 2021 - Elsevier
Background Long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA, also
known as dual bronchodilator) and inhaled corticosteroid/LABA (ICS/LABA) are the …
known as dual bronchodilator) and inhaled corticosteroid/LABA (ICS/LABA) are the …
Dual–Versus Mono–Bronchodilator Therapy in Moderate to Severe COPD: A Meta-analysis
M Lipari, PB Kale-Pradhan… - Annals of …, 2020 - journals.sagepub.com
Background: Chronic obstructive pulmonary disease (COPD) guidelines recommend both
long-acting and dual bronchodilator therapy. It is unclear if there are differences in efficacy …
long-acting and dual bronchodilator therapy. It is unclear if there are differences in efficacy …
Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how
L Calzetta, MG Matera, P Rogliani… - Expert Review of …, 2018 - Taylor & Francis
Dual bronchodilation therapy is the cornerstone for the treatment of chronic obstructive
pulmonary disease (COPD)[1]. Combining a long-acting β2 adrenoceptor (β2-AR) agonist …
pulmonary disease (COPD)[1]. Combining a long-acting β2 adrenoceptor (β2-AR) agonist …
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed …
Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …
Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive …
JC Samp, MJ Joo, GT Schumock… - … : The Journal of …, 2017 - Wiley Online Library
Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the …
Rationale: There is uncertainty on the optimal first-line therapy for symptomatic chronic
obstructive pulmonary disease (COPD). Long-acting β2-receptor agonists (LABAs) and long …
obstructive pulmonary disease (COPD). Long-acting β2-receptor agonists (LABAs) and long …
Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
相关搜索
- dual bronchodilator β2 agonist
- dual bronchodilator meta analysis
- safety profile bronchodilation therapy
- muscarinic antagonist inhaled corticosteroid
- bronchodilator therapy severe copd
- muscarinic antagonist beta2 agonist
- beta2 agonist inhaled corticosteroid
- acting bronchodilators combination therapy
- bronchodilator therapy meta analysis
- acting bronchodilators meta analysis
- bronchodilators alone combination therapy
- bronchodilators alone meta analysis
- severe copd meta analysis